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Ultimately, these findings demonstrate the need to further
study and characterize low-grade disease in black men. This
study was limited by short follow-up and possible unad-
justed confounding variables. Future studies with longer fol-
low-up will be needed to further characterize low-grade dis-
ease in black men and to determine the clinical significance
of the small absolute differences and whether they continue
to increase over time.
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COMMENT & RESPONSE
Controversies About Lyme Disease
To the Editor There are a number of inaccuracies in the View-
point by Drs Shapiro and Wormser on Lyme disease.1
First, they stated that “…there has not been a statistically
significant increase in the number of reported cases of Lyme
disease in the United States during the most recent 4 years
(2013-2016) for which data are available.” Quest Diagnostics
has reported a significant increase of positive Lyme disease test
results, with Lyme disease being detected in each of the
50 states and the District of Columbia.2
Second, the authors wrote “The vast majority of patients
with Lyme disease (≥90%) develop the characteristic skin le-
sion, erythema migrans.” The department of health in Maine
reported that between 2009 and 2012 only 48.25% of pa-
tients with Lyme disease had a typical rash.3,4
Third, I disagree with the statement that “For extracuta-
neous manifestations of Lyme disease, the sensitivity of an-
tibody tests is excellent (87%-100%).” A PubMed search for se-
ronegativity in Lyme borreliosis5 identified a large number of
cases. It is well known that untreated streptococcal pharyn-
gitis can progress to rheumatic fever, causing irreversible heart
damage. Untreated syphilis leads to progressive disability and
dementia, and untreated human immunodeficiency virus
infection progresses to AIDS with significant disability and
death. What happens to a patient with Lyme disease who goes
months, years, or decades before diagnosis because of a
false-negative serological test result? Shapiro and Wormser do
not discuss the consequences of untreated Lyme disease in
their Viewpoint.
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To the Editor The Viewpoint on Lyme disease1 contained state-
ments that are not entirely supported by current data. For
example, the authors stated that “The vast majority of pa-
tients with Lyme disease (≥90%) develop the characteristic skin
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lesion, erythema migrans.” According to the Centers for
Disease Control and Prevention (CDC), only 70% to 80% of pa-
tients with Lyme disease reported to its surveillance system
have an erythema migrans rash.2 Schutzer et al3 state that ery-
thema migrans may not occur or be recognized in 30% of cases,
and studies note uncharacteristic variants of erythema mi-
grans. The general public and even some clinicians find it chal-
lenging to decide whether a rash is erythema migrans. Aucott
et al4 reported that of 3104 people participating in a rash iden-
tification survey, 72.7% correctly identified the classic ery-
thema migrans rash associated with Lyme disease, whereas
24.2% incorrectly identified a tick-bite reaction as erythema
migrans. Although 20.5% of participants correctly identified
the 4 nonclassic rashes included in the survey, a large percent-
age of people would be misidentified and potentially not seek
prompt medical attention.4 These individuals are at in-
creased risk of developing more severe Lyme disease se-
quelae, such as posttreatment Lyme disease syndrome, which
was not discussed in the article.
Drs Shapiro and Wormser also wrote that “There is a com-
mon misconception that poor sensitivity of antibody tests for
Lymediseaseisamajorlimitation.”Two-tiertestingofearlyLyme
disease patients at baseline is only 40% sensitive, and sensitiv-
ity increases to only 67.5% after treatment.5 Poor diagnostic per-
formance during early Lyme disease is problematic because more
positive clinical outcomes are associated with earliest possible
diagnosis and initiation of treatment.
The authors went on to say, “However, this is a problem only
if clinicians erroneously depend on serologic tests to make a di-
agnosis of Lyme disease in patients with erythema migrans,
which typically precedes the development of detectable antibod-
ies.” Most patients do not recall a tick bite, 20% to 30% patients
do not present with erythema migrans,2 and not all rashes that
appear to be erythema migrans are.3 Thus, clinicians often must
rely on an individual’s case history combined with serological
testing to make a timely and accurate differential diagnosis.
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In Reply Mr Tuttle and Mr Santarella and Dr Sellati cite data from
passive surveillance systems as evidence that our statement
that erythema migrans develops in 90% or more of patients
with Lyme disease was inaccurate.1 However, multiple large
clinical studies2,3 have estimated the proportions of pediatric
and adult patients with Lyme disease with erythema mi-
grans. These estimates, which are much more reliable be-
cause patients were carefully assessed for the presence of ery-
thema migrans, have consistently equaled or exceeded 90%.
Lower proportions (eg, 70%) among cases reported to the CDC
likely reflect reporting bias toward clinical manifestations as-
sociated with seropositivity.4 The CDC also estimates that 90%
of cases of Lyme disease go unreported. Among cases re-
ported to the CDC, 30% had Lyme arthritis, in contrast to the
6% or lower frequency of this manifestation in prospective
clinical studies.2,3
The numbers of cases of Lyme disease reported to the CDC,
despite limitations in estimates, are a good way to monitor
trends in incidence. They confirm our statement that there has
not been a statistically significant increase in reported cases
during the last 4 years.4 There also is no significant differ-
ence in incidence of reported cases in the most recent 5-year
period compared with the preceding 5-year period.4 There has
been a substantial increase in incidence over the past 20 to 30
years, but this has been a gradual, modest increase, with sub-
stantial year-to-year variation, rather than a sudden explo-
sion of cases.
Reactive serological test results from Quest Diagnostics are
not a validated measure of the number of cases of Lyme dis-
ease that occur in the United States. There are numerous com-
mercial laboratories. An increase in the number of positive re-
sults reported by a given laboratory may simply reflect a change
in the number of tests performed rather than a true increase
in incidence of disease. In addition, it is not clear whether
1 patient could be represented multiple times, and the results
do not distinguish between a new-onset (incident) event and
a positive result that could have been present for many years.
We did not suggest that persons with Lyme disease should
not be treated. However, if the decision to treat a patient who
has a skin lesion that might be erythema migrans is based solely
on a positive serological test result, most patients with Lyme
disease will not be treated or treatment will be delayed be-
cause the skin lesion typically develops before antibodies are
detectable (ie, sensitivity is poor in early disease, but it is rarely
required because the rash is very characteristic).5 Con-
versely, to confirm Lyme disease as the cause of extracutane-
ous manifestations, a positive serological test result usually is
needed. Almost all such patients will have positive serology
(ie, sensitivity is excellent); however, a small proportion of pa-
tients with early neurological Lyme disease (<15%) will not have
seropositivity until repeat testing is performed 1 to 2 weeks af-
ter initial presentation. In contrast, patients with late Lyme dis-
ease (eg, Lyme arthritis) will usually have seropositivity for IgG
antibodies at the time of presentation.5,6 Seronegative late
Lyme disease is not an established entity.6
Eugene D. Shapiro, MD
Gary P. Wormser, MD
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Cardiovascular Health and Cognitive Decline
To the Editor In their population-based cohort study, Dr Sa-
mieri and colleagues1 found that positive measures of cardio-
vascular health were associated with a lower risk of dementia
and lower rates of cognitive decline. An important limitation
of the data analysis, however, is that the investigators did not
address the potential influence of depression or antidepres-
sant treatment on their cognitive outcomes of interest.
Depression is an independent risk factor for all-cause and
cardiac morbidity and mortality in patients with acute
coronary syndromes, may be an independent risk factor for in-
cident coronary heart disease, and is associated with a signifi-
cantly increased risk of stroke morbidity and mortality.2,3
Depression also is an accepted risk factor for dementia. Ap-
proximately 10% of Alzheimer disease cases can be attrib-
uted to depression, comparable with the attribution rate for
smoking and higher than the rates attributable to diabetes,
midlife hypertension, or midlife obesity.4 The largest propor-
tion of Alzheimer disease cases can be attributed to physical
inactivity and low educational attainment.4
Depression, midlife hypertension, midlife obesity, diabe-
tes, smoking, physical inactivity, and low educational attain-
ment are all risk factors for dementia, but they are not inde-
pendent of each other. At baseline, approximately 20% of
patients in the Three-City Study had a history of treated
depression, but depression occurrence and antidepressant
treatment during follow-up were not reported.
Antidepressant drugs activate and regulate intracellular
neurotrophic and neuroprotective processes.5 These intracel-
lular processes promote neurogenesis and are protective in
models of neurodegenerative diseases (including dementia)
and ischemia. Increased activity or overexpression of glyco-
gen synthase kinase 3 (GSK3) is associated with an increase in
tau hyperphosphorylation and alterations in amyloid-β pro-
cessing, which are related to the formation of neurofibrillary
tangles and plaques in dementia. Antidepressant drugs in-
hibit GSK3 activity and increase brain-derived neurotropic fac-
tor, which is involved in learning and memory and may be pro-
tective against the development of dementia.5
Because depression and antidepressant drug treatment
have a strong potential for modifying the neurobiological risk
of developing dementia, they should be considered in con-
junction with other cardiovascular risk factors.
Robert H. Howland, MD
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In Reply We agree with Dr Howland that depression is a comor-
bidity of primary importance in both cardiovascular diseases
and dementia. Depressive symptoms are prevalent in older
persons (eg, 12.6% of our study participants had high depres-
sive symptomatology based on validated cutoffs on the Cen-
ter for Epidemiologic Studies–Depression Scale, and 6.4% con-
sumed antidepressant medications at baseline1), and
depression may represent both a risk factor and a prodrome
of dementia.2
Moreover, higher depressive symptoms have been re-
lated to lower cardiovascular health levels in epidemiological
studies,3,4 suggesting that depression could represent a bar-
rier to reach optimal cardiovascular health. Our analyses in the
Three-City Study cohort confirmed the strong relationships be-
tween depressive symptomatology and both decreased lev-
els of cardiovascular health and increased dementia risk, as pre-
viously reported. The proportions of individuals with high
depressive symptoms or antidepressant use at baseline for
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